Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas

International Journal of Hematology

Volumn 83, Issue 1, 2006, Pages 66-73

  Cho, Hyun Il ^a   Hong, Young Seon ^b   Lee, Myung Ah ^b   Kim, Eun Kyung ^a   Yoon, Sung Hee ^a   Kim, Chun Choo ^a,b   Kim, Tai Gyu ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Adoptive transfer; Angiocentric lymphomas; Cancer immunotherapy; Cytotoxic T lymphocyte; Epstein Barr virus

Indexed keywords

BLEOMYCIN; CARMUSTINE; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISOLONE; PROCARBAZINE; THIOTEPA; VINCRISTINE SULFATE;

ADOPTIVE TRANSFER; ADULT; ANGIOCENTRIC LYMPHOMA; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; T CELL LYMPHOMA;

ADULT; CELL LINE; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOMA, NON-HODGKIN; MALE; NOSE NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 31644433917     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A30505     Document Type: Article

References (48)

1. Fechner RE, Lampin DW. Midline malignant reticulosis. Arch Otolaryngol. 1972;95:467-476.
2. Jaffe ES. Pathologic and clinical spectrum of post-thymic T-cell malignancies. Cancer Invest. 1984;2:413-426.
3. Lipford EH, Margolick JB, Longo DL, Fauci AS, Jaffe ES. Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferation. Blood. 1988;72:1674-1681.
4. Medeiros LJ, Peiper SC, Elwood L, Yano T, Raffeld M, Jaffe ES. Angiocentric immunoproliferative lesions: a molecular analysis of eight cases. Hum Pathol. 1991;22:1150-1157.
5. Ho FC, Srivastava G, Loke SL, et al. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and 'T' cell type. Hematol Oncol. 1990;8:271-281.
6. Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol Oncol. 1997;15:71-79.
7. Aviles A, Rodriguez L, Guzman R, Talavera A, Garcia EL, Diaz-Maquero JC. Angiocentric T-cell lymphoma of the nose, paranasal sinuses and hard palate. Hematol Oncol. 1992;10:141-147.
8. Ferry JA, Sklar J, Zukerberg LR, Harris NL. Nasal lymphoma: a clinicopathologic study with immunophenotypic and genotypic analysis. Am J Surg Pathol. 1991;15:268-279.
9. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20:103-111.
10. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54-63.
11. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 1998;83: 806-812.
12. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol. 1992;3:297-307.
13. Magrath I, Jain V, Bhatia K. Epstein-Barr virus and Burkitt's lymphoma. Semin Cancer Biol. 1992;3:285-295.
14. Thomas JA, Allday MJ, Crawford DH. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res. 1991;57:329-380.
15. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
16. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
17. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997;157:217-222.
18. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549-1555.
19. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998;9:5129-5132.
20. Roskrow MA, Suzuki N, Can Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91: 2925-2934.
21. Chua D, Huang J, Zheng B, et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001;94:73-80.
22. Comoli P, De Palma R, Siena S, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol. 2004;15:113-117.
23. Lucas KG, Salzman D, Garcia A, et al. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent. EBV-positive Hodgkin disease. Cancer 2004;100:1892-1901.
24. Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005;105:1898-1904.
25. Sadler AM, Petronzelli F, Krausa P, et al. Low-resolution DNA typing for HLA-B using sequence-specific primers in allele- or group-specific ARMS/PCR. Tissue Antigens. 1994;44:148-154.
26. Tiercy JM, Jeannet M, Mach B. A new approach for the analysis of HLA class II polymorphism: 'HLA oligotyping.' Blood Rev. 1990; 4:9-15.
27. Cho HI, Kim HJ, Oh ST, Kim TG. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine. 2003;22:224-236.
28. Cuadra-Garcia I, Proulx GM, Wu CL, et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol. 1999;23:1356-1369.
29. + NK lymphomas: clinicopathological features and prognosis. Br J Haematol. 1997;97: 821-829.
30. Liang R, Chen F, Lee CK, et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant. 1997;19:91-93.
31. Nawa Y, Takenaka K, Shinagawa K, et al. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:1321-1322.
32. + natural killer cell lymphomas. Leuk Lymphoma. 2001;42:1297-1303.
33. Okamura T, Kishimoto T, Inoue M, et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant. 2003;31: 105-111.
34. Frisan T, Sjoberg J, Dolcetti R, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood. 1995;86:1493-1501.
35. + Hodgkin's disease. Blood. 1997;89:1978-1986.
36. Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 2001; 61:6219-6226.
37. Kim GE, Lee SW, Chang SK, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol. 2001;61:261-269.
38. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436-442.
39. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47: 187-376.
40. Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol. 1997;71:267-275.
41. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989;320: 1731-1735.
42. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2:850-861.
43. Wheatley GH 3rd, McKinnon KP, Iacobucci M, Mahon S, Gelber C, Lyerly HK. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of post-transplantation lymphoma. Surgery. 1998;124:171-176.
44. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188: 1359-1368.
45. + killer T cells. J Exp Med. 2001;193:405-411.
46. Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer. 2001;93:706-713.
47. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003; 101:1905-1912.
48. Bollard CM, Straathof KC, Huls MH, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004;27:317-327.